Allyx Therapeutics, Inc. is a clinical-stage biotechnology company based in Durham, Connecticut, founded in 2018. The company focuses on developing disease-modifying treatments for Alzheimer's Disease, specifically aiming to reverse neurodegeneration. Allyx's lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator. This innovative approach enables healthcare providers to offer a therapy capable of preserving cognition in patients with Alzheimer's, addressing a significant unmet need in the treatment of this condition.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company based in Cambridge, Massachusetts, focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer’s disease. Incorporated in 2014, the company is advancing its lead product, AST-004, a novel small molecule designed for acute administration. This therapy aims to protect and repair damaged neurons by selectively stimulating astrocytes, a type of brain cell crucial for neuronal health. Astrocyte Pharmaceuticals is dedicated to demonstrating the neuroprotective benefits of its approach and improving outcomes for patients suffering from brain injuries.
Strategikon Pharma, Inc. is a technology firm that specializes in the design and development of software solutions aimed at optimizing the outsourcing processes in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a cloud-based platform that facilitates end-to-end management of clinical business operations, including planning, outsourcing, and financial management of clinical trials. This software creates a collaborative virtual environment that enhances communication and data integration between pharmaceutical companies and their service providers, moving away from traditional, labor-intensive methods such as Excel. By providing tools for clinical financial management, vendor performance metrics, and contract lifecycle management, Clinical Maestro enables biopharmaceutical firms to streamline their operations and reduce costs significantly. Founded in 2016 and headquartered in San Rafael, California, Strategikon also offers consulting services to support the establishment of clinical business operations for new entrants in the field.
Avisi Technologies Inc. is focused on developing innovative solutions to combat glaucoma, a leading cause of irreversible blindness. The company has created VisiPlate, a next-generation aqueous shunt designed for mid to late-stage glaucoma treatment. This product is notable for its ultrathin design, being 20 times thinner than a human hair, which facilitates a less invasive insertion procedure that reduces operating time and simplifies follow-up care. VisiPlate is constructed from alumina, a material recognized for its use in hip replacements, thus ensuring biocompatibility. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Avisi Technologies aims to address the challenges associated with current glaucoma treatments, including patient non-compliance and post-operative complications, ultimately striving to prevent blindness in affected individuals.
Watershed Therapeutics develops a novel, targeted drug-delivery platform for bladder diseases. The initial aim is to stop recurring urinary tract infections. The therapy can be tailored to help patients with overactive bladder, painful bladder syndrome, and bladder cancer.
Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile, a broad therapeutic window, and applications to many cancers.
Allyx Therapeutics, Inc. is a clinical-stage biotechnology company based in Durham, Connecticut, founded in 2018. The company focuses on developing disease-modifying treatments for Alzheimer's Disease, specifically aiming to reverse neurodegeneration. Allyx's lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator. This innovative approach enables healthcare providers to offer a therapy capable of preserving cognition in patients with Alzheimer's, addressing a significant unmet need in the treatment of this condition.
Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, which uniquely integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology facilitates the identification and characterization of rare cells that are vital to understanding biological pathways and diseases. Celldom's initial applications focus on oncology, immunology, and stem cell biology, providing researchers with advanced tools to explore cellular heterogeneity and improve scientific outcomes.
Strategikon Pharma, Inc. is a technology firm that specializes in the design and development of software solutions aimed at optimizing the outsourcing processes in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a cloud-based platform that facilitates end-to-end management of clinical business operations, including planning, outsourcing, and financial management of clinical trials. This software creates a collaborative virtual environment that enhances communication and data integration between pharmaceutical companies and their service providers, moving away from traditional, labor-intensive methods such as Excel. By providing tools for clinical financial management, vendor performance metrics, and contract lifecycle management, Clinical Maestro enables biopharmaceutical firms to streamline their operations and reduce costs significantly. Founded in 2016 and headquartered in San Rafael, California, Strategikon also offers consulting services to support the establishment of clinical business operations for new entrants in the field.
Anubis Bio Corporation is an animal health company based in Orlando, Florida, focused on developing and manufacturing medical nutrition products for pets. Founded in 2018, the company specializes in treatments for diarrhea in dogs and cats. Its flagship product, DoggyStat, utilizes passive immunity to deliver fast-acting immune factors directly to the gastrointestinal tract, providing symptomatic relief and addressing infections that cause diarrhea. Anubis Bio is dedicated to enhancing the health and well-being of pets through innovative solutions in veterinary care.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Sandstone Diagnostics offers a centrifuge system that provides plasma and serum collection at-home and the point-of-care. It specializes in the fields of clinical diagnostics, home healthcare, and fertility.
It was founded in 2012 and headquartered in Pleasanton, California.
BioTrace Medical is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. BioTrace Medical is a stealth-stage company focused on the production of medical devices.
The company was founded by Aravind Swaminathan and Ellis Garai in 2013 and is based in San Mateo, California.
Identical is a developer of personalized dental implants used to make tooth replacement more accessible and affordable for everyone. Its implants are drill-free and non-invasive and use the latest 3D technology that enables dentists to deliver personalized dental implants in a faster and safer way.
It was founded in 2018 and is headquartered in Walnut Creek, California.
Stimwave LLC is a medical device company focused on developing, manufacturing, and marketing wireless microsize injectable devices for neurology applications. The company's product offerings include the Freedom SCS System, a spinal cord stimulator designed to alleviate chronic low back and leg pain, and the StimQ PNS System, a peripheral nerve stimulator that addresses chronic pain by targeting specific peripheral nerves. Originally incorporated as Neural Micro Incorporated in 2010, Stimwave LLC is headquartered in Pompano Beach, Florida.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Eumentis Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodevelopmental and neurodegenerative diseases. Based in Newton, Massachusetts, the company focuses on synthesizing established therapeutic knowledge with contemporary insights into brain function. Its primary product, EM-036, is a nitroaminoadamantane NMDA receptor antagonist aimed at treating Alzheimer's disease and autism-spectrum disorders. In addition to its drug development efforts, Eumentis Therapeutics also offers pre-clinical study, development, and testing services, contributing to advancements in neuropharmaceutical treatments. Established in 2019, the company strives to enhance healthcare solutions in the field of neurology.
Inhalon Biopharma, Inc. is focused on developing monoclonal antibodies that utilize innovative technology to trap pathogens in mucus secretions, specifically targeting respiratory infections. Founded in 2018 and based in Carrboro, North Carolina, the company aims to provide treatments and preventative solutions for respiratory syncytial virus (RSV), a significant cause of lung and respiratory tract infections in children. Inhalon Biopharma's inhaled immunotherapy platform is designed to harness the power of biologics for mucosal applications, enabling healthcare providers to effectively address acute respiratory infections.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
Chameleon Biosciences Inc. specializes in developing gene therapy solutions using Adeno Associated Virus (AAV) technology to address rare genetic diseases. Founded in 2017 and based in San Anselmo, California, the company focuses on delivering therapeutic proteins to targeted tissues while minimizing immune responses to enhance gene delivery and reduce immunogenicity. Chameleon aims to transform the treatment landscape for genetic disorders, particularly in infants, where a significant percentage of fatalities are attributed to these conditions. The company is dedicated to ensuring that affected children receive accurate, lower-dose treatments that can be administered multiple times as needed. By masking foreign proteins and shielding the viral capsid from antibodies, Chameleon seeks to increase the range of diseases that can be treated effectively, thereby improving patient outcomes and quality of life.
TeVido BioDevices, Inc, a biotech start-up, develops tissue engineered products for reconstructive surgery. It operates a platform technology that uses 3D bio-printing and a patient’s living cells to build custom grafts that address unmet needs in the field of reconstructive and cosmetic surgery. The company was incorporated in 2016 and is based in Austin, Texas.
First Light Biosciences develops breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare-Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.
TransformativeMed, Inc. specializes in developing software solutions for hospitals and health application partners, focusing on enhancing the integration of electronic medical records (EMR) with clinician workflows. Founded in 2007 and based in Seattle, the company offers a range of Smart Health Apps, which are designed to facilitate seamless communication and data management within healthcare settings. Notable solutions include CORES Smart Handoffs, enabling efficient patient sign-outs between providers; GlycemiCare Smart Glucose, aimed at improving glycemic control and patient safety; and ACR Select Smart Imaging, which provides decision support for imaging at the point of order entry. TransformativeMed has established itself as a leader in EMR integration, empowering over 40 hospitals to maximize their EMR investments while focusing on improving patient outcomes.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
Purissima, Inc. is a biotherapeutics company founded in 2017 and headquartered in Sunnyvale, California. The company specializes in producing active pharmaceutical ingredient (API) grade molecules by leveraging a unique platform that utilizes the fermentation of heterotrophic microalgae. Through this innovative approach, Purissima aims to advance the development of biotherapeutics and contribute to the pharmaceutical industry.
Virion Therapeutics, LLC, a biotechnology company, develops immune-based treatments for virally-associated cancers and chronic viral infections. It offers ChiVax and ChiVax-gD vaccines to induce potent and sustained T cell-mediated immune responses against transformed and infected cells. Virion Therapeutics, LLC was incorporated in 2018 and is based in Newark, Delaware.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
TheraDep Technologies, Inc. manufactures biologic materials. It offers TheraDep, a technology solution that provides treatment for numerous medical conditions and influences the performance of various medical devices; TherGen, a solution that combines the therapeutic benefits of Cold Atmospheric Plasma (CAP) to apply a layer of collagen; BioDep, medical device coatings that offer coating deposition of biologic materials and drugs for the medical devices, and laboratory analysis equipment and supplies; and BioDep Labware offers a single step dry process to apply biologic materials used in diagnostics and laboratory equipment. The company was founded in 2015 and is based in Palo Alto, California.
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.
Ark.one Health develops a predictive analytics platform for health care systems and plans. The company provides financial performance improvement analytics to health systems as a service.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Thrive Bioscience, Inc. is a life science company based in Beverly, Massachusetts, focused on enhancing cell culture practices through innovative technology. Established in 2014, the company specializes in automated non-microbial cell culture instruments and software that facilitate research, drug discovery, drug development, and regenerative medicine. Its flagship product, CellAssist, allows cell culture researchers to efficiently image, analyze, and document various cells and workflows within a centralized database. By integrating microscopy, robotics, and fluidics, Thrive's instruments enable biologists to achieve consistent and reproducible results while providing comprehensive analysis, reports, and guidance on cell culture processes.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
Retrotope Inc. is a biotechnology company that focuses on developing drugs for the treatment of degenerative and intractable diseases, particularly neurological disorders. Based in Los Altos, California, the company aims to preserve and restore mitochondrial health through a novel drug platform that targets metabolic processes linked to oxidative stress. Retrotope's portfolio includes RT001, a drug designed for infantile neuroaxonal dystrophy, and it actively works on treatments for conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. Established in 2006, Retrotope employs innovative approaches, including the isotope effect, to slow damaging biological pathways, thereby addressing various major classes of biopolymers and advancing its commitment to improving patient outcomes in degenerative diseases.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Physcient, Inc. is a Durham, North Carolina-based company that specializes in the manufacture of surgical instruments, particularly the Differential Dissector, which is designed for blunt dissection. This device is utilized in various surgical fields, including plastic surgery and open general procedures such as thoracic, gastrointestinal, gynecological, urological, peripheral vascular, and orthopedic surgeries. Founded in 2007 by three experienced professionals with extensive backgrounds in life and health sciences technology, Physcient aims to enhance surgical efficiency and promote quicker recovery for patients without altering existing surgical techniques.
Carmenta Bioscience is a privately held medical technology company dedicated to improving maternal and fetal health. Spun-out of Stanford University School of Medicine in 2012, Carmenta Bioscience is currently developing a highly accurate, serum-based diagnostic test for preeclampsia.
NuMedii, Inc. is a biotechnology company focused on the discovery, development, and out-licensing of drug candidates. Utilizing proprietary Life Sciences Big Data technology, originally developed in Atul Butte’s lab at Stanford University, NuMedii analyzes vast amounts of biological, pharmacological, and clinical data to identify new therapeutic applications for existing drugs and to discover new molecular entities. The company partners with pharmaceutical firms to facilitate the clinical development and commercialization of its de-risked drug candidates. Founded in 2008, NuMedii is headquartered in San Mateo, California, and maintains strategic alliances with organizations like Aptalis Pharma and Three Lakes Partners, LLC.
Nanostim is an early-stage medical device company working to prevent more than 100,000 annual complications related to pacemakers. Nanostim has assembled a world-class team of experienced medical device engineers to help bring this exciting technology to the marketplace.
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California.
nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation.
Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Niveus Medical, Inc. develops and provides muscle stimulation systems designed to maintain and improve the strength of key muscle groups, particularly the quadriceps, during periods of sedation and bed rest. Founded in 2008 and located in Redwood City, California, the company's technology, branded as IntelliSTIM, is indicated for enhancing range of motion in the knee joint, preventing disuse atrophy, re-educating muscles, relieving muscle spasms, and promoting local blood circulation. These systems facilitate quicker treatment initiation in intensive care settings, thereby increasing the likelihood of successful recovery outcomes for patients.
MoMelan Technologies, Inc. operates as a developer of a device to treat skin disorders by expanding the surface area of skin grafts. The company was incorporated in 2009 and is based in Cambridge, Massachusetts. MoMelan Technologies, Inc. operates as a subsidiary of Acelity L.P. Inc.
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.
Velomedix, Inc. is a therapeutic hypothermia company in the United States. Its therapeutic hypothermia technology offers a novel solution for the protection of the body's organs during ischemic or inflammatory insults. Velomedix, Inc. is based in Menlo Park, California.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
Breathe Technologies, Inc was founded in 2005 with the objective of empowering healthcare providers and patients with new, reliable and accessible respiratory therapies that optimize breathing and mobility.
They are in the process of developing truly ultra-light, compact, patient-friendly ventilator systems that can transform respiratory care in the hospital and home markets.
Satoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. They're committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.
Fluxion Biosciences was formed in 2005 to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
VasoNova, Inc. manufactures and markets medical devices. It develops a self-guided PICC catheter. The company is based in Sunnyvale, California.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.
NSpine, Inc. engages in designing and developing devices for stabilization and motion preservation of the lumbar spine via minimally invasive surgery. Its product includes NFlex, a titanium pedicle screw system, which provides support to the spinal motion segment and also used in non-fusion/hybrid applications.
Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.